This study developed and evaluated an optimized intramuscular patient-derived xenograft (PDX) platform for gastric cancer. The model achieved a high engraftment rate of 71.7%, significantly exceeding conventional methods. Researchers utilized whole exome sequencing to identify divergent driver mutations between fast- and slow-growing tumors. The findings suggest that PDX-guided chemotherapy selection is associated with improved progression-free survival, and that driver mutation profiles can serve as prognostic biomarkers.
This study performed integrated genomic, transcriptomic, and DNA methylation profiling on 76 desmoid tumors (DTs), uncovering frequent mutations in chromatin-remodeling genes, notably KMT2C, in addition to the known CTNNB1 and APC mutations. Transcriptomic analysis identified two robust molecular subtypes: immune-myogenic and mesenchymal-like. The immune-myogenic subtype exhibited high expression of myogenic markers and immune checkpoint genes, alongside enhancer hypomethylation. This subtype is associated with increased immune cell infiltration and predicts a higher responsiveness to immune checkpoint inhibitors.
Clear cell adenocarcinoma of the urinary tract (CCA-UT) is a rare and aggressive tumor with limited understanding of its clinicopathologic and molecular features. This multi-institutional study characterized 35 cases, showing a female predominance and advanced stage at presentation. Genomic alterations were found in 91% of cases, frequently involving chromatin modifiers such as ATRX, KMT2C, ARID1A, and ARID1B. The heterogeneous molecular profile of these tumors highlights the critical role of molecular analysis in identifying potential therapeutic targets.